Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751906 · ClinicalTrials.gov registry record · NA
ABSORB III Randomized Controlled Trial (RCT)
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,008
- Enrollment target
NCT01751906 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,008 participants.
The verdict
NCT01751906, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,008 participants
- Enrollment target
Study Summary
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS). The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study and ABSORB IV RCT trial which are maintained under one protocol because both trial designs are related, ABSORB IV is the continuation of ABSORB III and the data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.
Interventions
- DEVICE XIENCE
- DEVICE Absorb BVS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,008 participants |
| Start Date | 2012-12 |
| Est. Completion | 2020-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751906
The ClinicalTrials.gov registry entry for NCT01751906 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,008 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT01751906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01751906 about?
NCT01751906 is a clinical study titled "ABSORB III Randomized Controlled Trial (RCT)". The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS). The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study and A...
What is the current status of trial NCT01751906?
This trial is currently completed. It is a NA study. The enrollment target is 2,008 participants. The study started on 2012-12. Estimated completion is 2020-10.
What interventions are being tested in trial NCT01751906?
The interventions under investigation include: XIENCE (DEVICE), Absorb BVS (DEVICE).
Who is sponsoring clinical trial NCT01751906?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.